356 related articles for article (PubMed ID: 33814914)
1. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
Cipriano É; Mesquita A
Breast Cancer (Auckl); 2021; 15():11782234211002491. PubMed ID: 33814914
[TBL] [Abstract][Full Text] [Related]
2. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
4. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F; Venturini S; Giuliano M; Lambertini M; Pinato DJ; Onesti CE; De Placido P; Harbeck N; Lüftner D; Denys H; Van Dam P; Arpino G; Zaman K; Mustacchi G; Gligorov J; Awada A; Campone M; Wildiers H; Gennari A; Tjan-Heijnen V; Bartsch R; Cortes J; Paris I; Martín M; De Placido S; Del Mastro L; Jerusalem G; Curigliano G; Prat A; Generali D
Cancer Treat Rev; 2022 Dec; 111():102468. PubMed ID: 36202026
[TBL] [Abstract][Full Text] [Related]
5. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
6. Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
Barchiesi G; Roberto M; Verrico M; Vici P; Tomao S; Tomao F
Front Oncol; 2021; 11():769280. PubMed ID: 34900718
[TBL] [Abstract][Full Text] [Related]
7. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
Tolaney SM; DeMichele A; Takano T; Rugo HS; Perou C; Lynce F; Parsons HA; Santa-Maria CA; Rocque GB; Yao W; Sun SW; Mocci S; Partridge AH; Carey LA
Future Oncol; 2024 Jun; ():1-21. PubMed ID: 38922307
[TBL] [Abstract][Full Text] [Related]
8. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
9. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer.
Kagihara JA; Shagisultanova E; Afghahi A; Diamond JR
Curr Breast Cancer Rep; 2021 Sep; 13(3):216-226. PubMed ID: 34457184
[TBL] [Abstract][Full Text] [Related]
10. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
11. Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies.
Kanwal B
Cureus; 2021 Jul; 13(7):e16636. PubMed ID: 34458041
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
Desai NV; Tan AR
JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
[TBL] [Abstract][Full Text] [Related]
13. Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report.
di Mauro P; Schivardi G; Pedersini R; Laini L; Esposito A; Amoroso V; Laganà M; Grisanti S; Cosentini D; Berruti A
Front Oncol; 2023; 13():1139372. PubMed ID: 36890829
[TBL] [Abstract][Full Text] [Related]
14. Metastatic triple-negative breast cancer: Established and emerging treatments.
Puri A; Reddy TP; Patel TA; Chang JC
Breast J; 2020 Sep; 26(9):1793-1796. PubMed ID: 32578306
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging biologic therapies for triple negative breast cancer.
Shaikh SS; Emens LA
Expert Opin Biol Ther; 2022 May; 22(5):591-602. PubMed ID: 32713217
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapies in Triple-Negative Breast Cancer.
Marmé F; Schneeweiss A
Breast Care (Basel); 2015 Jul; 10(3):159-66. PubMed ID: 26557820
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
Ferrari P; Scatena C; Ghilli M; Bargagna I; Lorenzini G; Nicolini A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163586
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
20. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
